Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases.

  • Devesa, Ana
  • Delgado, Victoria
  • Valkovic, Ladislav
  • Lima, Joao A C
  • Nagel, Eike
  • Ibanez, Borja
  • Raman, Betty
Cardiometabolic diseases encompass a group of conditions characterized by metabolic and inflammatory abnormalities that increase the risk of diabetes and cardiovascular disease. These syndromes involve multiple organs, including the heart, arterial system, brain, skeletal muscle, adipose tissue, hematopoietic system, liver, kidneys, and pancreas. The crosstalk between these organs contributes to the development of disease. Advances in imaging techniques, such as magnetic resonance imaging, magnetic resonance spectroscopy, computed tomography, and positron emission tomography, have revolutionized the evaluation of these conditions. Hybrid imaging modalities, such as positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging, provide unique insights into the anatomy and metabolic alterations occurring in response to cardiometabolic risk factors. These methods are particularly valuable for assessing multisystemic involvement and interorgan crosstalk, revealing critical interactions such as the brain-heart axis, the heart-liver axis, and the fat-muscle-heart dynamics. This review discusses the role of state-of-the-art imaging techniques in evaluating the pathophysiological mechanisms underlying these complex syndromes and the clinical applications of the different imaging techniques in the assessment of cardiometabolic diseases.
Repisalud
Publicación Artículo científico (JournalArticle)

Imidazole propionate is a driver and therapeutic target in atherosclerosis.

  • Mastrangelo, Annalaura
  • Robles-Vera, Iñaki
  • Mañanes, Diego
  • Galán, Miguel
  • Femenía-Muiña, Marcos
  • Redondo-Urzainqui, Ana
  • Barrero-Rodríguez, Rafael
  • Papaioannou, Eleftheria
  • Amores-Iniesta, Joaquín
  • Devesa, Ana
  • Lobo-González, Manuel
  • Carreras, Alba
  • Beck, Katharina R
  • Ivarsson, Sophie
  • Gummesson, Anders
  • Georgiopoulos, Georgios
  • Rodrigo-Tapias, Manuel
  • Martínez-Cano, Sarai
  • Fernández-López, Ivan
  • Nuñez, Vanessa
  • Ferrarini, Alessia
  • Inohara, Naohiro
  • Stamatelopoulos, Kimon
  • Benguría, Alberto
  • Cibrian, Danay
  • Sánchez-Madrid, Francisco
  • Alonso-Herranz, Vanesa
  • Dopazo, Ana
  • Barbas, Coral
  • Vázquez, Jesús
  • López, Juan Antonio
  • González-Martín, Alicia
  • Nuñez, Gabriel
  • Stellos, Konstantinos
  • Bergström, Göran
  • Bäckhed, Fredrik
  • Fuster, Valentín
  • Ibañez, Borja
  • Sancho, David
Atherosclerosis is the main underlying cause of cardiovascular diseases. Its prevention is based on the detection and treatment of traditional cardiovascular risk factors. However, individuals at risk for early vascular disease often remain unidentified. Recent research has identified new molecules in the pathophysiology of atherosclerosis, highlighting the need for alternative disease biomarkers and therapeutic targets to improve early diagnosis and therapy efficacy. Here, we observed that imidazole propionate (ImP), produced by microorganisms, is associated with the extent of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration to atherosclerosis-prone mice fed with chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and was linked to activation of both systemic and local innate and adaptive immunity and inflammation. Specifically, we found that ImP caused atherosclerosis through the imidazoline-1 receptor (I1R, also known as nischarin) in myeloid cells. Blocking this ImP-I1R axis inhibited the development of atherosclerosis induced by ImP or high-cholesterol diet in mice. Identification of the strong association of ImP with active atherosclerosis and the contribution of the ImP-I1R axis to disease progression opens new avenues for improving the early diagnosis and personalized therapy of atherosclerosis.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3-F4 patients

  • Carvalho-Gomes, Ângela
  • Valcheva, Tsveta Vladi
  • Sahuco, Ivan
  • Vidal, Enrique
  • Martínez-Arenas, Laura
  • Vinaixa, Carmen
  • Aguilera, Victoria
  • García García, Sonia
  • Berenguer, Marina
[EN] Background & AimsSeveral hepatocellular carcinoma (HCC) risk-models have been developed to individualise patient surveillance following sustained viral response (SVR) in Hepatitis C Virus patients. Validation of these models in different cohorts is an important step to incorporate a more personalised risk assessment in clinical practice. We aimed at applying these models to stratify the risk in our patients and potentially determine cost-saving associated with individualised HCC risk-stratification screening strategy. MethodsPatients with baseline F3-4 fibrosis treated with new oral direct-acting antivirals who had reached a SVR were regularly followed as part of the HCC surveillance strategy. Six models were applied: Pons, aMAP, Ioannou, HCC risk, Alonso and Semmler. Validation of the models was performed based on sensitivity and the proportion of patients labelled as "high risk". ResultsAfter excluding 557 with less than 3 fibrosis, 12 without SVR, 18 with a follow up (FU) <1 year, 17 transplant recipients, 16 lost to FU and 31 with HCC at time of antiviral therapy, our cohort consisted of 349 F3-4 SVR patients. Twenty-three patients (6.6%) developed HCC after a median FU of 5.12 years. The sensitivity of the different models varied between 0.17 (Semmler7noalcohol) and 1 (Alonso A and aMAP). The lowest proportion of high-risk patients corresponded to the Semmler-noalcohol model (5%). Sixty-three and 90% of the Alonso A and aMAP patients, respectively were labelled as high risk. The most reliable HCC risk-model applied to our cohort to predict HCC development is the Alonso model (based on fibrosis stage assessed by liver stiffness measurements or Fibrosis-4 index (FIB-4) at baseline and after 1 year, and albumin levels at 1 year) with a-100% sensitivity in detecting HCC among those at high risk and 63% labelled as high risk. The application of the model would have saved the cost of 1290 ultrasound no longer being performed in the 37% low-risk group. ConclusionIn our cohort, the Alonso A model allows the most reliable reduction in HCC screening resulting in safely stopping life-long monitoring in about a third of F3-F4 patients achieving SVR with DAAs.; image, Instituto de Salud Carlos III, Grant/Award Numbers: FI20/00033, INT20/00061, PI19/01360; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas; Gilead Research Scholars, Grant/Award Number: GLD18-192
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Experimental Setup for Irradiation of Cell Cultures at L2A2

  • Torralba, Alberto
  • Palenciano-Castro, Lidia
  • Reija, Alicia
  • Rigla, Juan Pablo
  • Peñas, Juan
  • Llerena, Juan José
  • Contreras-Martinez, Ramiro
  • Benlliure, José
  • Vega, Ana
  • Aguado-Barrera, Miguel Elías
  • Ruiz, Camilo
  • Seimetz, Michael
[EN] Laser-plasma proton sources and their applications to preclinical research has become a very active field of research in recent years. In addition to their small dimensions as compared to classical ion accelerators, they offer the possibility to study the biological effects of ultra-short particle bunches and the correspondingly high dose rates. We report on the design of an experimental setup for the irradiation of cell cultures at the L2A2 laboratory at the University of Santiago de Compostela, making use of a 1.2 J Ti: Sapphire laser with a 10 Hz repetition rate. Our setup comprises a proton energy separator consisting of two antiparallel magnetic fields realized by a set of permanent magnets. It allows for selecting a narrow energy window around an adaptable design value of 5 MeV out of the initially broad spectrum typical for Target Normal Sheath Acceleration (TNSA). At the same time, unwanted electrons and X-rays are segregated from the protons. This part of the setup is located inside the target vessel of the L2A2 laser. A subsequent vacuum flange sealed with a thin kapton window allows for particle passage to external sample irradiation. A combination of passive detector materials and real-time monitors is applied for measurement of the deposited radiation dose. A critical point of this interdisciplinary project is the manipulation of biological samples under well-controlled, sterile conditions. Cell cultures are prepared in sealed flasks with an ultra-thin entrance window and analysed at the nearby Fundacion Publica Galega Medicina Xenomica and IDIS. The first trials will be centred at the quantification of DNA double-strand breaks as a function of radiation dose., Projects RTI2018-101578-B-C21 and RTI2018-101578-B-C22 are funded by MCIN/AEI /10.13039/501100011033 and by FEDER "Una manera de hacer Europa". Project AICO/2020/207 is funded by Generalitat Valenciana. Supports PEJ2018-002035-A and PEJ2018-002037-A are financed by AEI and "El FSE invierte en tu futuro". Additional funding is by FPI predoctoral grant BES-2017-08917 and Unidad de Excelencia Maria de Maeztu, MdM-2016-0692-17-2. Action is co-financed by the European Union through the Programa Operativo del Fondo Europeo de Desarrollo Regional (FEDER) of the Comunitat Valenciana 2014-2020 (IDIFEDER/2018/022 and IDIFEDER/2021/004). FPGMX-IDIS research is partially supported by the Spanish Instituto de Salud Carlos III (ISCIII) funding, which is an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (INT20/00071, PI19/01424, AC18/00117) and through the Autonomous Government of Galicia (Consolidation and structuring program: IN607B) given to A. Vega.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

FibroScan compared to liver biopsy for accurately staging recurrent hepatic steatosis and fibrosis after transplantation for MASH

  • Martínez-Arenas, Laura
  • Vinaixa, Carmen
  • Conde, Isabel
  • Lorente, Sara
  • Díaz-Fontenla, Fernando
  • Marques, Patrice
  • Pérez-Rojas, Judith
  • Montalvá, Eva
  • Carvalho-Gomes, Ângela
  • Berenguer, Marina
[EN] Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) recurrence after liver transplantation (LT) seems unavoidable and gradual. We aimed to evaluate the diagnostic accuracy in the post-LT setting of patients transplanted for metabolic dysfunction-associated steatohepatitis (MASH) of recurrent hepatic steatosis and fibrosis identified with FibroScan, compared to biopsy findings. Methods: This prospective cohort study included adults transplanted for MASH between 2010 and 2022 in three LT centres in Spain who underwent FibroScan and biopsy at least 1-year after LT. Results: In total, 44 patients transplanted for MASH after LT were included. The median time from LT to biopsy and FibroScan was 24.5 (interquartile range [IQR]:16-46) and 26.0 (IQR: 16.8-41.5) months, respectively. The median time between biopsy and FibroScan was 2.0 (IQR: 0-5) months. On FibroScan, significant steatosis was diagnosed in about half of the patients (n = 21, 47.7%), yet advanced fibrosis in only two cases (4.6%). On biopsy, a quarter of biopsied patients (n = 11, 25%) had a MASH diagnosis, two (4.6%) with significant fibrosis and one (2.3%) with cirrhosis. All patients with liver stiffness measurement (LSM) values <8 kPa (n = 35, 79.5%) had a fibrosis stage ¿F1 (negative predictive value = 100%). The combination of post-LT hypertension (odds ratio [OR]: 12.0, 95% confidence interval [CI]: 1.8-80.4, p = .010) and post-LT dyslipidaemia (OR: 7.9, 95% CI: 1.3-47.1, p = .024) with LSM (OR: 1.7, 95% CI: 1.1-2.8, p = .030) was independently associated with MASLD. Conclusions: Although biopsy remains the gold standard for detecting fibrosis, our results suggest that LSM values <8 kPa after LT for MASH are strongly correlated with absence of significant/advanced fibrosis., Generalitat Valenciana; Instituto de Salud Carlos III; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas; Sociedad Espanola de Trasplante Hepatico This research was funded by the Instituto de Salud Carlos III and co- funded by European Regional Development Fund 'A way to make Europe' (grant PI19/01360 to MB, grant INT20/00061 to MB, grant FI20/00033 to LMA, grant MV22/00053 to LMA, grant CD22/00045 to PM, grant PI23/00088 to MB, and grant INT24/00021 to MB), by the Generalitat Valenciana (grant AICO/2021/035 to MB, grant CIGE/2023/073 to PM, and grant CIPROM/2023/16 to MB), by the CIBER -Consorcio Centro de Investigacion Biomedica en Red- [CB06/04/0065], Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and Union Europea-European Regional Development Fund, and by the Spanish Society of Liver Transplantation (SETH, grant 2022/295 to MB).
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Hippocampal subfield abnormalities and biomarkers of pathologic brain changes: from SARS-CoV-2 acute infection to post-COVID syndrome

  • Díez-Cirarda, María
  • Yus-Fuertes, Miguel
  • Sanchez-Sanchez, Rafael
  • González Rosa, Javier Jesús
  • Gonzalez-Escamilla, Gabriel
  • Gil-Martínez, Lidia
  • Delgado Casas, Cándida Inés
  • Gil-Moreno, María José
  • Valles-Salgado, María
  • Cano Cano, Fátima
  • Ojeda-Hernandez, Denise
  • Gomez-Ruiz, Natividad
  • Oliver-Mas, Silvia
  • Benito-Martín, María Soledad
  • Jorquera, Manuela
  • de la Fuente, Sarah
  • Polidura, Carmen
  • Selma-Calvo, Belén
  • Arrazola, Juan
  • Matias-Guiu, Jordi
  • Gomez-Pinedo, Ulises
Background: Cognitive deficits are among the main disabling symptoms in COVID-19 patients and post-COVID syndrome (PCS). Within brain regions, the hippocampus, a key region for cognition, has shown vulnerability to SARS-CoV-2 infection. Therefore, in vivo detailed evaluation of hippocampal changes in PCS patients, validated on post-mortem samples of COVID-19 patients at the acute phase, would shed light into the relationship between COVID-19 and cognition. Methods: Hippocampal subfields volume, microstructure, and perfusion were evaluated in 84 PCS patients and compared to 33 controls. Associations with blood biomarkers, including glial fibrillary acidic protein (GFAP), myelin oligodendrocyte glycoprotein (MOG), eotaxin-1 (CCL11) and neurofilament light chain (NfL) were evaluated. Besides, biomarker immunodetection in seven hippocampal necropsies of patients at the acute phase were contrasted against eight controls. Findings: In vivo analyses revealed that hippocampal grey matter atrophy is accompanied by altered microstructural integrity, hypoperfusion, and functional connectivity changes in PCS patients. Hippocampal structural and functional alterations were related to cognitive dysfunction, particularly attention and memory. GFAP, MOG, CCL11 and NfL biomarkers revealed alterations in PCS, and showed associations with hippocampal volume changes, in selective hippocampal subfields. Moreover, post mortem histology showed the presence of increased GFAP and CCL11 and reduced MOG concentrations in the hippocampus in post-mortem samples at the acute phase. Interpretation: The current results evidenced that PCS patients with cognitive sequalae present brain alterations related to cognitive dysfunction, accompanied by a cascade of pathological alterations in blood biomarkers, indicating axonal damage, astrocyte alterations, neuronal injury, and myelin changes that are already present from the acute phase. Funding: Nominative Grant FIBHCSC 2020 COVID-19. Department of Health, Community of Madrid. Instituto de Salud Carlos III through the project INT20/00079, co-funded by European Regional Development Fund “A way to make Europe” (JAMG). Instituto de Salud Carlos III (ISCIII) through Sara Borrell postdoctoral fellowship Grant No. CD22/00043) and co-funded by the European Union (MDC). Instituto de Salud Carlos III through a predoctoral contract (FI20/000145) (co-funded by European Regional Development Fund “A way to make Europe”) (MVS). Fundación para el Conocimiento Madri+d through the project G63-HEALTHSTARPLUS-HSP4 (JAMG, SOM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oral saliva swab reverse transcription PCR for Covid-19 in the paediatric population

  • Moraleda, Cinta
  • Domínguez-Rodríguez, Sara
  • Mesa, Juan Miguel
  • García Sánchez, Paula
  • de la Serna, María
  • Alonso-Cadenas, José Antonio
  • Bermejo, Amanda
  • Sabrido, Gema
  • Martínez-Campos, Leticia
  • González-Posada, Aránzazu Flavia
  • Illán-Ramos, Marta
  • Cobos-Carrascosa, Elena
  • Ballesteros, Álvaro
  • Galán, Juan Carlos
  • Llorente, Francisco
  • Aguilera-Alonso, David
  • Jiménez, Ana Belén
  • Catalán, Pilar
  • Dahdouh, Elias
  • Navarro, Ignacio
  • Fernández-Garoz, Bárbara
  • Mendoza, Pablo
  • Pérez-Jorge, Concepción
  • Cabezas-Fernández, Teresa
  • Blázquez-Gamero, Daniel
  • Rivas, Gonzalo
  • Gonzalez-Donapetry, Patricia
  • Sáez, Elena
  • Fernández-Pinero, Jovita
  • Lucas-Fernández, Jesús
  • Pérez-Ramírez, E.
  • Merino, Paloma
  • Miragaya, Sandra
  • Lorente, Jorge
  • Iglesias, Irene
  • Tagarro, Alfredo
8Pág. Centro de Investigación en Sanidad Animal (CISA), To evaluate the performance of oral saliva swab (OSS) reverse transcription PCR (RT-PCR) compared with RT-PCR and antigen rapid diagnostic test (Ag-RDT) on nasopharyngeal swabs (NPS) for SARS-CoV-2 in children., The study was funded by: Project PI20/00095, from the Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) and cofounded by the European Regional Development Fund, by Infanta Sofia University Hospital and Henares University Hospital Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN), and by SERMAS-Fundación para la Investigación Biomédica del Hospital 12 de Octubre. EC-C is supported by the Spanish Society of Paediatrics (Asociación Española de Pediatría); Grant COVID-19 EPICO-AEP 2020. JMM is funded by SERMAS-Fundación para la Investigación Biomédica del Hospital Infanta Sofía y del Henares and by Universidad Europea de Madrid, Spain. MdlS is funded by Grant Cantera de Investigación Santander, Fundación Universidad Europea de Madrid, Spain. ED is funded by the Juan de la Cierva–Incorporación granted by the Spanish Ministry of Science and Innovation. DB-G is funded by the Spanish Ministry of Science and Innovation—Instituto de Salud Carlos III and Fondos FEDER by ’Contratos para la intensificación de la actividad investigadora en el Sistema Nacional de Salud, 2020 (INT20/00086)’., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Waiting time dictates impact of frailty: A Spanish multicenter prospective study

  • Puchades, Lorena
  • Herreras, Julia
  • Ibañez, Ana
  • Reyes, Érick
  • Crespo, Gonzalo
  • Rodríguez-Perálvarez, Manuel
  • Cortés, Luis
  • Serrano, Trinidad
  • Fernández-Yunquera, Ainhoa
  • Montalvá, Eva
  • Berenguer, Marina
Background & aims: Frailty is prevalent in liver transplant (LT) candidates. It is considered an independent predictor of adverse outcomes pre- and post-transplant according to data obtained in the United States. We aimed to externally validate the liver frailty index (LFI) in a multicenter cohort of LT candidates. Methods: Outpatients with cirrhosis were prospectively recruited from five Spanish centers (2018-2020). Patients were defined as "frail" by an optimal cut-off of LFI ≥4.5. Patients were followed for at least 6 months to study associations of pre-LT frailty with pre- and post-transplant mortality, length of hospital and intensive care unit (ICU) stays, risk of early (<30 days) and late (30-90 days) post-transplant complications, retransplantation and cardiovascular events. Results: Of 212 patients included, 45 patients (21%) were frail pre-LT, and the median LFI was 3.9 (IQR 3.5-4.4). After a median waiting time of 78 days, 2% died or were delisted for clinical worsening. The LFI at baseline was not predictive of mortality/delisting in LT candidates in univariable or multivariable analyses after adjusting for age and MELD-Na score (hazard ratio 1.48; p = 0.586). In contrast, compared to non-frail patients, frail LT candidates had a significantly higher length of hospital stay (9 vs. 13 days; p = 0.001) and rate of early (<30 days) post-transplant complications (55% vs. 100%; p = 0.021). Conclusions: In the context of a short LT waiting time, frailty does not impact pretransplant mortality and/or delisting. In contrast, LT frailty is predictive of higher post-transplant complication rates and length of hospital stay. Whether strategies aimed at pre- and/or re-habilitation are beneficial in settings with short waiting times needs to be confirmed in prospective studies. Impact and implications: Literature is scarce on the actual impact of physical frailty on adverse outcomes in the liver transplant scenario outside North America. Evidence-based justification to extend the use of objective frailty tools in the decision-making processes in other liver transplant settings is needed. This study is the first to evaluate the predictive value of the liver frailty index in outpatients in the European liver transplant setting, showing that in a low MELD, high access system, frailty does not impact pretransplant mortality and/or delisting but is predictive of higher complication rates and longer post-transplant length of stay. In practical ways, physicians should consider physical frailty as a vital sign to be measured systematically and routinely during clinic visits; researchers are encouraged to initiate prospective studies to evaluate the benefit of applying strategies aimed at pre- and or re-habilitation in liver transplant settings with short waiting times.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The placental transcriptomic profile determined by maternal COVID-19 disease encompasses alterations reminiscent of preeclampsia

  • Medel-Martinez, Ana
  • Strunk, Mark
  • Cebollada-Solanas, Alberto
  • Puente-Santamaría, Laura
  • Gómez-Muñoz, Sonia
  • Fabre, Marta
  • Paules, Cristina
  • Oros, Daniel
  • Schoorlemmer, Jon
Introduction. During initial stages of the pandemic, SARS-CoV-2 infection during pregnancy was related to adverse pregnancy outcomes and alterations in the placenta. Whether placental abnormalities in pregnant women with COVID-19 still persist afterwards remains poorly studied. Here, we determined whether the absence of obstetric complications after maternal COVID-19 disease, including preeclampsia, is accompanied by a complete return to normalcy in terms of placental physiology. Methods. Placental RNA was purified from placental samples from SARS-CoV-2 positive mothers taken either in 2022, when Omicron was the predominant variant of concern (termed Omicron) (n = 21); or from healthy pregnancies predating the pandemic (termed preCOVID-19). Our cohort included samples from pregnant women who got infected weeks and even months before term. We performed RNA-seq, identified differentially expressed genes and examined to which biological, biochemical and cellular pathways they belong, using gene set enrichment analysis. Results. We identified 71 differentially expressed genes (DEGs) (defined by p-value ≤0.05 and fold change (FC) of ≤ -2 or ≥2). The alterations identified in placentas delivered by mothers who suffered an episode of COVID-19 disease could be mainly attributed to pathways related to organogenesis, extracellular matrix organization and oxygen transport. These alterations were also detected after exclusion of gestational diabetes mellitus (GDM) samples. Although none of the samples were taken from cases of preeclampsia, several of the relevant DEGs have been previously reported as dysregulated in hypertensive disorders of pregnancy including preeclampsia. Discussion. We propose that maternal SARS-CoV-2 infection causes alterations in gene expression that are indicative of vascular defects in the placenta
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Towards an understanding of COVID-19-associated preeclampsia

  • Medel-Martinez, A.
  • Cebollada-Solanas, A.
  • Strunk, M.
  • Fabre, M.
  • Fernández-Soria, V. M.
  • Ramos-Ruiz, R.
  • Paules, C.
  • Oros, D.
  • Schoorlemmer, J.
Introduction SARS-CoV-2 infection during pregnancy has been associated with higher rates of preeclampsia (PE). While placental abnormalities resembling PE have been reported in COVID-19 pregnancies, the molecular mechanisms underlying the association remain unclear. Methods We conducted bulk RNA sequencing on placental tissues from four pregnancy groups: uneventful prepandemic (preCOVID-19), prepandemic PE (preCOVID-19 PE), COVID-19 without PE (COVID no PE), and COVID-19 complicated by PE or other hypertensive disorders (COVID PE). Differential expression was analyzed using Deseq2 likelihood ratio test (LRT), and gene set enrichment analysis identified dysregulated pathways. Results Clustering of LRT-significant differentially expressed genes (DEGs) identified a set of 16 genes (defined by the false discovery rate adjusted p-value < 0.05) across the four pregnancy groups, showing stepwise expression changes—lowest in preCOVID-19 uneventful, followed by those in COVID-19 without PE, then preCOVID-19 PE, and highest in COVID PE. This cluster included genes associated with placental dysfunction, such as LAMA5 and BTNL9. While morphogenesis-related pathways were enriched across all pathological groups, immune activation pathways were predominantly enriched in COVID PE, moderately in preCOVID-19 PE, and absent in COVID no PE. Discussion Our findings identify a COVID-19–associated placental signature that mirrors PE features and shows a progressive expression pattern defining a continuum of placental stress, with maternal SARS-CoV-2 infection potentially exacerbating underlying dysfunction.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Alterations of placental HERV expression as a result of gestational COVID-19 disease

  • Medel-Martinez, Ana
  • Bugatti, Mattia
  • Polychronopoulou, Mariana
  • Strunk, Mark
  • Macías-Redondo, Sofía
  • Bazo, Andrea
  • Garrido-Pontnou, Marta
  • Kitsou, Konstantina
  • Fabre, Marta
  • Paules, Cristina
  • Oros, Daniel
  • Pierquin, Justine
  • Brunel, Joanna
  • Charvet, Benjamin
  • Perron, Hervé
  • Facchetti, Fabio
  • Magiorkinis, Gkikas
  • Schoorlemmer, Jon
Introduction: Activation of human endogenous retroviral elements (HERV) is a well-documented phenomenon in inflammatory pathologies including COVID-19, with HERVW ENV frequently mentioned as a toxic protein. Given that COVID-19 during pregnancy has been associated with placental damage and a higher risk of adverse pregnancy outcomes (APOs), we investigated whether gestational COVID-19 alters placental HERV expression, and if such alterations correlate with placental damage or dysfunction. Methodology and results: We quantitively analyzed mRNA expression of HERV in placental samples using qPCR assays rigorously tested for efficiency and specificity or transcriptomic analysis. Combined qPCR and transcriptomic analyses of placentas from maternal COVID-19 cases revealed an overall trend toward reduced expression of several HERV elements, including HERVW ENV-related transcripts, with a more pronounced downregulation in SARS-CoV-2-positive placentas. HERVW ENV protein was detected by immunofluorescence in the syncytiotrophoblast (STB), co-staining with HCGβ, using conditions minimizing cross-reactivity with ERVWE1. HERVW ENV protein levels were diminished in COVID-19 patients, especially in those cases in which SARS-CoV-2 was present in the placenta. Conclusions and discussion: While HERV expression is reportedly induced in blood lymphocytes and other tissues as a response to SARS-CoV-2 infection, we detect unaltered or lower RNA levels of selected retroviral elements in the placenta of COVID-19 patients. HERVW ENV protein was present in non-COVID-19 placenta, and downregulated by maternal COVID-19 disease. The absence of HERVW ENV protein induction was confirmed by the careful study of cases with placental SARS-CoV-2 infection, as HERVW ENV was mostly absent from these samples, probably as an indirect result of placental damage. We identified two independent triggers for the downregulation of both HERVW ENV RNA and protein in placenta: maternal COVID-19 and local effects of SARS-CoV-2. Therefore, this HERV downregulation may represent part of the molecular response to placental SARS-CoV-2 infection, contributing to placental dysfunction and APOs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Autoantibody screening in Guillain-Barré syndrome

  • Lleixà, Cinta|||0000-0002-9971-0584
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Franco Leyva, Teresa|||0000-0002-0250-0274
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Suárez Calvet, Xavier|||0000-0002-5314-6607
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Homedes, C.
  • Gutiérrez-Gutiérrez, Gerardo
  • Jimeno-Montero, M. C.
  • Berciano, José|||0000-0001-9261-9748
  • Sedano-Tous, M. J.
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Pardo, Julio|||0000-0001-8807-1310
  • Márquez-Infante, C.
  • Rojas-Marcos, I.|||0000-0003-4142-4283
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Martínez Hernández, Eugenia
  • Morís, Germán|||0000-0001-7608-2194
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Background: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain-Barré syndrome. Methods: Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed. Results: None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors. Conclusion: Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies targeting nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic value; (3) further antigen-discovery experiments may elucidate other potential antigens in GBS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)

  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mur, Isabel|||0000-0001-7660-8483
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Vidal, Francesc|||0000-0002-6692-6186
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
Introduction: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation

  • Masip, Jenifer|||0000-0002-9233-5195
  • Jorba, Rosa|||0000-0003-3307-4340
  • López Dupla, Jesús Miguel|||0000-0002-9141-2523
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Martínez, Esteban|||0000-0002-6911-8846
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Alba, Verónica|||0000-0002-5925-9573
  • Olona, Montserrat|||0000-0001-5303-9361
  • Vidal, Francesc|||0000-0002-6692-6186
  • Gómez-Bertomeu, Frederic
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Nuclear magnetic resonance (NMR)-based advanced lipoprotein tests have demonstrated that LDL and HDL particle numbers (LDL-P and HDL-P) are more powerful cardiovascular (CV) risk biomarkers than conventional cholesterol markers. Of interest, in people living with HIV (PLHIV), predictors of preclinical atherosclerosis and vascular dysfunction may be associated with impaired immune function. We previously stated that immunological non-responders (INR) were at higher CV risk than immunological responders (IR) before starting antiretroviral therapy (ART). Using Liposcale tests, we characterized the lipoprotein profile from the same cohort of PLHIV at month 12 and month 36 after starting ART, intending to explore what happened with these indicators of CV risk during viral suppression. ART initiation dissipates the differences in lipoprotein-based CV risk markers between INR and IR, and only an increase in the number of HDL-P was found in INR + IR when compared to controls (p = 0.047). Interestingly, CD4 T-cell counts negatively correlated with medium HDL-P concentrations at month 12 in all individuals (ρ = -0.335, p = 0.003). Longitudinal analyses showed an important increase in LDL-P and HDL-P at month 36 when compared to baseline values in both IR and INR. A proper balance between a proatherogenic and atherogenic environment may be related to the reconstitution of CD4 T-cell count in PLHIV.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Rajabally, Yusuf
  • Scotton, Sangeeta
  • Jacobs, Bart C.|||0000-0002-8985-2458
  • Baars, Adája Elisabeth|||0000-0001-7842-0871
  • Cortese, Andrea
  • Vegezzi, Elisa|||0000-0001-8776-6831
  • Höftberger, Romana|||0000-0002-5769-1100
  • Zimprich, Fritz|||0000-0002-6998-5480
  • Roesler, Cornelia
  • Nobile-Orazio, Eduardo|||0000-0003-2624-8138
  • Liberatore, Giuseppe|||0000-0003-2666-1678
  • Hiew, Fu Liong|||0000-0002-4708-3734
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Carvajal, Alejandra
  • Piñar Morales, Raquel|||0000-0003-3490-4932
  • Usón-Martín, Mercedes
  • Albertí, Olalla
  • López Pérez, María Ángeles
  • Márquez, Fabian
  • Pardo-Fernández, Julio
  • Muñoz-Delgado, Laura|||0000-0002-8818-1824
  • Cabrera-Serrano, Macarena|||0000-0003-3109-6095
  • Ortiz-Castellon, Nicolau|||0000-0001-9544-2642
  • Bartolomé, Manuel
  • Duman, Özgür
  • Bril, Vera
  • Segura-Chávez, Darwin
  • Pitarokoili, Kalliopi
  • Steen, Claudia
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Background and ObjectivesTo study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN).MethodsPatients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up.ResultsForty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients.DiscussionAnti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases.Classification of EvidenceThis study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab.